Musculoskeletal Inflammation is an indication for drug development with over 70 pipeline drugs currently active. According to GlobalData, preregistered drugs for Musculoskeletal Inflammation have a 83.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Musculoskeletal Inflammation compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Musculoskeletal Inflammation overview

Musculoskeletal inflammation refers to the body’s response to irritation, injury, or infection affecting muscles, bones, joints, ligaments, or tendons. Conditions like arthritis, tendinitis, bursitis, or muscle strains often trigger this response. Inflammation manifests as pain, swelling, stiffness, and reduced mobility in the affected area. Causes vary—from overuse or trauma to autoimmune disorders like rheumatoid arthritis. Treatment aims to reduce inflammation and manage symptoms, involving rest, ice or heat therapy, medications (such as NSAIDs or corticosteroids), physical therapy, or lifestyle modifications. In chronic cases, ongoing management focuses on controlling inflammation to improve quality of life and maintain functionality.

For a complete picture of PTSR and LoA scores for drugs in Musculoskeletal Inflammation, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.